A phase 1 study found topical sildenafil cream was linked with lower systemic exposure than oral sildenafil and was well tolerated in healthy men.
Related to this article
In this episode, Karen Bigman, MBA, joins to discuss sexual health, intimacy, and relationship challenges facing adults as they navigate midlife and beyond.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to SpaceOAR Flex Hydrogel for prostate radiotherapy
2
Real-World Outcomes and Learning Curve for Drug-Coated Balloon BPH Therapy
3
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
4
After curative-intent treatment, prostate cancer recurrence is still an unmet need
5